Huangyang Meng
No. 300 Guangzhou Road
Nanjing, 210029, China
Nanjing, 210029, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity.
Journal: Science advances
Published: April 15, 2026
FRα expression in borderline ovarian tumors and low-grade serous ovarian carcinoma: prognostic and immune microenvironmental associations.
Journal: Journal of ovarian research
Published: February 24, 2026
Tumour-derived SAA1 reprogrammes macrophages to promote CXCL1-mediated metastasis in Ovarian Cancer.
Tumour-derived SAA1 reprogrammes macrophages to promote CXCL1-mediated metastasis in Ovarian Cancer.
Journal: Clinical and translational medicine
Published: February 12, 2026
Overcoming Ferroptosis-Induced Exhaustion of NK Cells through Inhibition of the ATF3-Mediated Integrated Stress Response in Ovarian Cancer.
Journal: International journal of biological sciences
Published: February 21, 2025
YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification.
Journal: Cancer letters
Published: March 24, 2024
Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancer.
Journal: International journal of biological sciences
Published: January 22, 2024
Derivation and validation of a nomogram based on clinical characteristics to diagnose endometriosis associated ovarian cancer preoperatively.
Journal: Journal of cancer research and clinical oncology
Published: August 23, 2023
FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism.
Journal: Cell death and differentiation
Published: August 11, 2023
Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China.
Journal: Medicine
Published: April 14, 2023
Bractoppin, a BRCA1 carboxy-terminal domain (BRCT) inhibitor, suppresses tumor progression in ovarian borderline tumor organoids.
Journal: Biochemical and biophysical research communications
Published: November 14, 2022
Visceral obesity determined by CT as a predictor of short-term postoperative complications in patients with ovarian cancer.
Journal: Archives of gynecology and obstetrics
Published: October 12, 2022
Identification of the Prognostic Signature Associated With Tumor Immune Microenvironment of Uterine Corpus Endometrial Carcinoma Based on Ferroptosis-Related Genes.
Journal: Frontiers in cell and developmental biology
Published: July 01, 2021
Last Updated: 09/26/2026